Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leukotriene antagonists.

Timothy J Davern1, Nathan M Bass

  • 1University of California, Division of Gastroenterology, 513 Parnassus Avenue, Room S-357, San Francisco 94143, CA, USA. tdavern@itsa.ucsf.edu

Clinics in Liver Disease
|July 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging Issues in Gastroenterology and Hepatology.

Gastroenterology & hepatology·2023
Same author

Indeterminate etiology of acute liver failure in North America: Less common, still grave prognosis.

Clinical transplantation·2023
Same author

A Brief History of Hepatic Encephalopathy.

Clinical liver disease·2021
Same author

Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in Premenopausal Women With NAFLD.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2020
Same author

Association Between Cytokines and Liver Histology in Children with Nonalcoholic Fatty Liver Disease.

Hepatology communications·2017
Same author

Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.

Hepatology (Baltimore, Md.)·2016
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

Drug-induced liver injury, known as hepatotoxicity, is a major concern, especially with new medications. This review examines liver injury risks associated with a novel class of asthma drugs.

Area of Science:

  • Pharmacology
  • Hepatology
  • Toxicology

Background:

  • Hepatotoxicity is a primary cause of acute liver failure in the US.
  • Drug-induced liver injury is a significant reason for medication withdrawal from the market.
  • There is increasing recognition of the medical, financial, and regulatory impact of drug-induced liver injury.

Purpose of the Study:

  • To review published data on liver injury associated with a novel group of asthma medications.
  • To assess the safety profile of new asthma drugs concerning hepatotoxicity.

Main Methods:

  • Literature review of published studies.
  • Analysis of case reports and clinical trial data on liver injury.
  • Focus on a novel class of asthma therapeutics.

Related Experiment Videos

Main Results:

  • Data on liver injury related to the novel asthma drug class was compiled.
  • The review specifically addresses concerns of hepatotoxicity in the context of these new drugs.

Conclusions:

  • The study highlights the importance of monitoring for liver injury with new asthma medications.
  • Understanding hepatotoxicity is crucial for drug safety and regulatory assessment.